Quality of Evidence:
Coadministration has not been studied. A clinically significant effect on clarithromycin is unlikely as it is mainly metabolized by CYP3A4. However, tenofovir-DF (the prodrug of tenofovir) is a substrate of P-gp and inhibitors of P-gp such as clarithromycin could potentially increase the absorption of tenofovir-DF, thereby increasing the systemic concentration of tenofovir. Monitoring of tenofovir-associated adverse reactions, including frequent renal monitoring, is recommended.
View all available interactions with
Tenofovir-DF (TDF) by clicking